Levetiracetam

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. By modulating this protein, the drug decreases neuronal hyper‑excitability and stabilizes synaptic transmission, thereby lowering the likelihood of seizure initiation and spread.

The specific dose of Levetiracetam is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Levetiracetam is classified as Pregnancy Category B, indicating no evidence of fetal risk in animal studies, but human data are limited. It may be used during pregnancy if the benefit outweighs potential risk. Breastfeeding mothers should discuss possible infant exposure with their healthcare provider.

To request Levetiracetam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Compared with older antiepileptics such as carbamazepine or phenytoin, Levetiracetam has a distinct mechanism targeting SV2A and generally fewer drug‑enzyme interactions. It is often favored for its broad spectrum of seizure control and a relatively favorable side‑effect profile, though individual response varies.

Levetiracetam tablets or oral solution should be stored below 25 °C (77 °F) in their original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve potency and stability throughout the product’s shelf life.

Levetiracetam can be given orally as tablets, capsules, or liquid, and intravenously for patients who cannot take oral medication. The route and formulation are selected by the prescriber based on clinical need, patient ability to swallow, and urgency of seizure control.

Serious risks include severe allergic reactions (e.g., rash, swelling, breathing difficulty), psychiatric effects such as depression or suicidal thoughts, and rare blood disorders like leukopenia. Patients should be monitored for any new or worsening symptoms and seek medical attention promptly if serious reactions occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting medications that may significantly alter its effectiveness.